[ad_1]
Targeted Therapies, Immunotherapies … the therapeutic arsenal against the most dangerous of skin cancers, metastasized melanoma, has grown considerably over the past decade. Disrupting the prognosis of this disease
"About 70% of patients respond to targeted therapies and 15 to 30% to immunotherapies, with a clear improvement in overall survival, but we are now confronted with the problem of recurrences. Many patients relapse, regardless of the type of treatment, and there are always patients who, from the start, do not respond to …
[ad_2]
Source link
